News - Page 30 of 34 - MaRS Innovation

BioCentury Features Xagenic’s PCR-Based Infection-Diagnosis Technology

Xagenic, a MaRS Innovation spin-off company, was featured in the most recent issue of BioCentury. Here's an excerpt (the article only available to BioCentury subscribers): PCR-based diagnosis of infections can delay treatment decisions by days or hours because the method relies on technical expertise and equipment not available in most point-of-care settings. Xagenic Inc.'s chip-based arrays use a non-PCR, electrochemical approach to diagnose bacterial infections at the point of care in 20 minutes with PCR-like accuracy. Xagenic's core technology is a silicon chip containing ... Read more

Los Angeles Times covers Dr. Gregory Czarnota’s cancer therapy technology

The Los Angeles Times featured Dr. Gregory Czarnota's research in their Science Now section on July 10, 2012, which reports on discoveries from the world of science and medicine (update: the article is no longer available online). Czarnota, a researcher at the Sunnybrook Health Sciences Centre, is working with MaRS Innovation to license his patented technology: radiosensitization of tumour cells using a combination of microbubbles and targeted, high-intensity, focused ultrasound. (more…) Read more

MaRS Innovation’s Lead Start-Up Completes $20 Million Series B

Xagenic’s financing round to test platform and first diagnostic assay, continue product development and begin FDA submission Toronto, ON (December 2, 2013) — MaRS Innovation’s first start-up company, Xagenic Inc., is developing the first lab-free molecular diagnostic platform with a 20-minute time-to-result based on University of Toronto research by Professors Shana Kelley and Edward Sargent. Today, Xagenic announced it has successfully closed a Series B financing round totaling $20 million. New investor Domain Associates, LLC, led the round, joined by existing investors who ... Read more

Business Without Borders features Encycle Therapeutics, Raphael Hofstein

Encycle Therapeutics, a MaRS Innovation spin-off company, was featured by Business Without Borders' High Tech section in a Q&A profile with MI's President and CEO, Raphael Hofstein. Here's an excerpt: Business Without Borders (BWB): What makes Encycle’s technology so promising? Raphael Hofstein (RH): Proteins are made of smaller units called peptides, usually existing as linear chains. If they get into the bloodstream, they get degraded rapidly by enzymes and they find it very difficult to get into cells of the body. What we want ... Read more

Raphael Hofstein’s editorial in National Post’s Medical Devices supplement

MaRS Innovation's President and CEO, Raphael Hofstein, has published an editorial outlining the challenges facing entrepreneurs seeking to bring new healthcare innovations to market for the National Post's Medical Devices supplement. The article, titled "Investing in innovation for a healthier Canada," is available on page 2 of the Post supplement. Posted by Elizabeth Monier-Williams, marketing and communications officer. Read more

Vice-President Joel Liederman to participate in Financial Post’s live chat on Canadian commercialization challenges

Joel Liederman, MaRS Innovation's vice-president of Business Development and Physical Sciences, is participating in a live chat on the Financial Post's website. The chat will take place on June 28, 2012 at 2 pm. Topic: Why Canada can't do anything with its big ideas When it comes to academic research and the development or discovery of new concepts or product models, there are few countries in the world that can hold a candle to Canada. (more…) Read more

Flybits featured as Canadian tech export in UKTI Youtube video

U.K. Trade and Investment (UKTI) has posted a Youtube video featuring Canadian companies looking to expand their operations to Britain. Flybits, a Mars Innovation spin-off company, was among three companies to be profiled: http://www.youtube.com/watch?v=9VrtJuSkYqY Flybits is launching a corporate presence in East London's Tech City, which is also known as the Silicon Roundabout. (more…) Read more

Montreal’s La Presse covers life science research funding project among MI, CQDM, OCE and OBI

This week, MaRS Innovation (MI) announced a new partnership agreement with The Québec Consortium for Drug Discovery (CQDM), the Ontario Brain Institute (OBI) and Ontario Centres of Excellence (OCE) to launch the Québec/Ontario CQDM Funding Program. The funding program will support collaborative life science research projects between the two provinces that seek to develop new tools for biopharmaceutical research. (more…) Read more

Raphael Hofstein’s guest blog for the Ontario Ministry of Economic Development and Innovation

At the 2012 BIO International Convention in Boston this week, MaRS Innovation, The Québec Consortium for Drug Discovery (CQDM), the Ontario Brain Institute and the Ontario Centres of Excellence announced we are launching a new life sciences funding program within the Ontario-Québec Corridor. The Ontario-Québec Life Sciences Corridor was itself announced at the 2011 BIO International Convention. Shortly thereafter, Max Felhmann, president and CEO of CQDM, and Raphael Hofstein, president and CEO of MaRS Innovation, decided to collaborate on a joint pilot ... Read more

CQDM Partners with MaRS Innovation, Ontario Brain Institute and Ontario Centres of Excellence to Launch Life Sciences Funding Program Within Ontario-Québec Corridor

BOSTON, MA, June 18, 2012 — Together with key partners from Ontario, The Québec Consortium for Drug Discovery (CQDM) is creating a new initiative to fund collaborative life sciences research projects between the two provinces. A French version of this release is available via CQDM's website. This initiative is the first notable and concrete realization of the Ontario-Québec Life Sciences Corridor, announced at the 2011 BIO International Convention. It builds upon two previous pilot projects and existing strengths within the two provinces to ... Read more
Page 30 of 34« First...1020...2829303132...Last »